Mineralys Therapeutics (Nasdaq: MLYS) will report fourth quarter and full year 2025 financial results after market close on Thursday, March 12, 2026.
The company will host a conference call and live webcast at 4:30 p.m. ET on that date; dial-in numbers, conference ID 13758574, and a webcast link will be available on the Investor Relations News & Events page.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MLYS
+2.44%2.3x vol
33 alerts
+2.44%Session close to close
+18.5%Peak Tracked
-6.3%Trough Tracked
$2.44BMarket Cap
2.3xRel. Volume
In the Mar 9 session, MLYS gained 2.44%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +18.5% during that session.
Argus tracked a trough of -6.3% from its starting point during tracking.
Our momentum scanner triggered 33 alerts that day, indicating elevated trading interest and price volatility.
Trading volume was elevated at 2.3x the daily average, suggesting notable buying interest.
This announcement sets the timetable for Mineralys’ fourth quarter and full year 2025 results and ac...
Analysis
This announcement sets the timetable for Mineralys’ fourth quarter and full year 2025 results and accompanying conference call on March 12, 2026. It follows recent clinical and corporate milestones for lorundrostat and a series of equity-related filings. Investors may focus on how the forthcoming financials and guidance frame the path from recent NDA filing and Phase 3 data toward potential commercialization and longer-term capital needs.
Large inducement option grant to a new non-executive employee.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Positive clinical and recognition news for lorundrostat has coincided with mild positive reactions, while routine inducement or compensation updates have shown mixed or minimal impact.
Recent Company History
Over the last several months, Mineralys has focused on advancing lorundrostat, highlighted by a corporate update on Jan 06, 2026 detailing three positive trials and an NDA filing, and JAMA recognition of its Phase 3 Launch-HTN trial on Dec 12, 2025. Other releases mainly covered inducement equity awards. Against this backdrop, the current earnings date announcement fits into an ongoing transition from clinical development toward commercialization-oriented milestones.
Key Terms
chronic kidney disease, ckd, obstructive sleep apnea, osa, +1 more
5 terms
chronic kidney diseasemedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)"
Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.
ckdmedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)"
Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and fluids from the blood, like household filters that slowly clog and underperform over time. It matters to investors because CKD drives demand for drugs, medical devices, diagnostics and dialysis services, influences healthcare spending and reimbursement decisions, and creates regulatory or clinical-trial risks and market opportunities across the healthcare sector.
obstructive sleep apneamedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)"
Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.
osamedical
"chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases"
Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.
aldosteronemedical
"other diseases driven by dysregulated aldosterone, today announced it will report"
Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.
RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2025, after the financial markets close on Thursday, March 12, 2026.
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
When will Mineralys Therapeutics (MLYS) report Q4 and full year 2025 results?
Mineralys Therapeutics will report results after market close on Thursday, March 12, 2026. According to the company, the release covers the fourth quarter and full year ended December 31, 2025 and precedes a conference call at 4:30 p.m. ET.
What time is the Mineralys Therapeutics (MLYS) conference call on March 12, 2026?
The conference call is scheduled for 4:30 p.m. ET on March 12, 2026. According to the company, a live webcast will also be available on the Investor Relations News & Events page for remote listeners.
How can investors join the Mineralys Therapeutics (MLYS) March 12, 2026 call?
Investors can join via domestic dial-in 1-877-704-4453 or international 1-201-389-0920 with conference ID 13758574. According to the company, a live webcast link will also be provided on the Investor Relations page.
Where will the Mineralys Therapeutics (MLYS) webcast be available for the March 12, 2026 call?
The webcast will be available on the company’s Investor Relations News & Events page. According to the company, the live webcast accompanies the conference call at 4:30 p.m. ET on March 12, 2026.
What period do Mineralys Therapeutics (MLYS) financial results cover in the March 12, 2026 announcement?
The results cover the fourth quarter and full year ended December 31, 2025. According to the company, those financial results will be released after market close on March 12, 2026 and discussed on the subsequent call.
